Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
August 08 2024 - 4:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of August 2024
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Purple Biotech Ltd. (the
“Company” or the “Registrant”) is announcing the results of the Annual General Meeting of Shareholders
of the Company held on August 8, 2024, at the Company’s offices (the “Meeting”). At the Meeting, the shareholders
of the Company voted on the proposals described in the Company’s Proxy Statement for the Meeting that was attached as Exhibit 99.1
to a Report of Foreign Private Issuer on Form 6-K furnished by the Company to the U.S. Securities and Exchange Commission on June 26,
2024 (the “Proxy Statement”).
Each of the proposals
presented for approval at the Meeting was approved by the requisite vote of the Company’s shareholders in accordance with the Israeli
Companies Law, 5759-1999 and the Company’s articles of association, as described in the Proxy Statement.
Accordingly, at the Meeting, the shareholders approved the following
proposals: (i) the re-election of Issac Israel to serve as a third class director, for a three-year term until the annual general meeting
to be held in 2027, and until his successor is duly elected and qualified; and (ii) the re-election of Suzana Nahum-Zilberberg to serve
as a third class director, for a three-year term until the annual general meeting to be held in 2027, and until her successor is duly
elected and qualified.
Incorporation by Reference
This Report on Form 6-K, including all exhibits
attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with
the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement
on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s
Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration
file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on
March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities
and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on
Form F-1 filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrant’s
Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229),
the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration
file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission
on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrant’s Registration
Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), the Registrant’s
Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration
file number 333-268710), the Registrant’s Registration Statement on Form F-1, as amended, originally filed with the Securities
and Exchange Commission on October 30, 2023 (Registration file number 333-275216) and the Registrant’s Registration Statement on
Form F-1, filed with the Securities and Exchange Commission on July 22, 2024 (Registration file number 333- 280947), to be a part thereof
from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
August 8, 2024 |
PURPLE BIOTECH LTD. |
|
|
|
By: |
/s/ Lior Fhima |
|
|
Lior Fhima |
|
|
Chief Financial Officer |
2
Purple Biotech (NASDAQ:PPBT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Purple Biotech (NASDAQ:PPBT)
Historical Stock Chart
From Aug 2023 to Aug 2024